阿仑膦酸钠在治疗严重骨折继发的骨质疏松症方面显示出显著的临床优势。
Alendronate sodium demonstrates significant clinical advantages in treating osteoporosis secondary to severe fractures.
作者信息
Wang Shenggen, Ye Lili, Hang Qiong
机构信息
Department of Orthopedics, Xinrui Hospital of Xinwu District Wuxi 214000, Jiangsu, PR China.
Department of Intensive Care Unit, Dantu District People's Hospital Zhenjiang 212000, Jiangsu, PR China.
出版信息
Am J Transl Res. 2025 Jun 15;17(6):4516-4523. doi: 10.62347/MFPV8667. eCollection 2025.
OBJECTIVE
To investigate the clinical efficacy of alendronate sodium in patients with osteoporosis secondary to severe fractures.
METHODS
A total of 102 patients with post-fracture osteoporosis were retrospectively included in this study. The control group (n=45) received standard treatment, while the research group (n=57) was additionally administered alendronate sodium. Bone metabolism markers, pain intensity (assessed by Visual Analogue Scale [VAS]), bone mineral density (BMD), and overall therapeutic efficacy were compared between the two groups. Multivariate logistic regression was performed to identify predictors of therapeutic efficacy.
RESULTS
Compared with the control group, the research group demonstrated significantly greater improvements in bone metabolism markers, VAS scores, BMD, and overall efficacy. Univariate and multivariate logistic regression analyses further identified smoking history, alcohol abuse, and treatment modality as independent risk factors for treatment failure, while elevated serum bone Gla protein (BGP) levels were identified as a protective factor.
CONCLUSION
Alendronate sodium significantly improves clinical outcomes in treating patients with osteoporosis secondary to severe fractures.
目的
探讨阿仑膦酸钠治疗严重骨折继发骨质疏松症患者的临床疗效。
方法
本研究回顾性纳入102例骨折后骨质疏松症患者。对照组（n = 45）接受标准治疗，研究组（n = 57）额外给予阿仑膦酸钠治疗。比较两组患者的骨代谢标志物、疼痛强度（采用视觉模拟评分法[VAS]评估）、骨密度（BMD）及总体治疗效果。进行多因素logistic回归分析以确定治疗效果的预测因素。
结果
与对照组相比，研究组在骨代谢标志物、VAS评分、BMD及总体疗效方面的改善更为显著。单因素和多因素logistic回归分析进一步确定吸烟史、酗酒和治疗方式是治疗失败的独立危险因素，而血清骨钙素（BGP）水平升高是保护因素。
结论
阿仑膦酸钠可显著改善严重骨折继发骨质疏松症患者的临床结局。
Zotero 插件